Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?
https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400
Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.
0
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
https://www.zacks.com/stock/news/2224881/what-s-in-the-cards-for-medtronic-mdt-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2224881
Feb 12, 2024 - Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
0
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
https://www.zacks.com/stock/news/2222832/exelixis-exel-q4-earnings-beat-on-lower-r-d-spend-sales-miss?cid=CS-ZC-FT-analyst_blog|earnings_article-2222832
Feb 07, 2024 - Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
0
IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?
https://www.zacks.com/stock/news/2217329/idexx-laboratories-idxx-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217329
Jan 29, 2024 - Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.
0
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213712
Jan 22, 2024 - Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
0
What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
https://www.zacks.com/stock/news/2213563/what-s-in-store-for-zimmer-biomet-zbh-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213563
Jan 22, 2024 - Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
0
TransCode (RNAZ) Down 50% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213010
Jan 19, 2024 - TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
0
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213007
Jan 19, 2024 - ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
0
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsp-s-casgevy-gets-fda-nod-for-thalassemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211622
Jan 17, 2024 - This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
0
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
0
<Page 2